Skip to main content
. 2024 Dec 6;15:1503154. doi: 10.3389/fphar.2024.1503154

FIGURE 1.

FIGURE 1

Serious adverse events identified for EV and Erdafitinib using WHO-VigiAccess, including life-threatening events, hospitalization, and disease progression. The proportion of reports indicating serious adverse reactions is 3.56% for EV and 11.85% for Erdafitinib.